# reload+after+2024-01-21 20:44:39.467025
address1§1851 Harbor Bay Parkway
city§Alameda
state§CA
zip§94502
country§United States
phone§650 837 7000
fax§650 837 8300
website§https://www.exelixis.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
fullTimeEmployees§1223
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Stelios  Papadopoulos Ph.D.', 'age': 75, 'title': 'Co-Founder & Independent Chair of the Board', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 109000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael M. Morrissey Ph.D.', 'age': 62, 'title': 'CEO, President & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 2310289, 'exercisedValue': 0, 'unexercisedValue': 1446800}, {'maxAge': 1, 'name': 'Mr. Christopher J. Senner', 'age': 55, 'title': 'Executive VP & CFO', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1088958, 'exercisedValue': 2929500, 'unexercisedValue': 156000}, {'maxAge': 1, 'name': 'Mr. Jeffrey J. Hessekiel J.D.', 'age': 54, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 959684, 'exercisedValue': 0, 'unexercisedValue': 126750}, {'maxAge': 1, 'name': 'Mr. Patrick J. Haley M.B.A.', 'age': 47, 'title': 'Executive Vice President of Commercial', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 844636, 'exercisedValue': 1759757, 'unexercisedValue': 296000}, {'maxAge': 1, 'name': 'Dr. Dana T. Aftab Ph.D.', 'age': 60, 'title': 'Executive VP of Discovery and Translational Research & Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan T. Hubbard', 'title': 'Executive Vice President of Public Affairs & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Laura  Dillard', 'title': 'Executive Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter  Lamb Ph.D.', 'age': 62, 'title': 'Executive VP of Scientific Strategy', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 909455, 'exercisedValue': 10719354, 'unexercisedValue': 908350}, {'maxAge': 1, 'name': 'Dr. Anne  Champsaur M.D.', 'title': 'Senior Vice President of Drug Safety', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§4
shareHolderRightsRisk§4
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.594
priceToSalesTrailing12Months§4.072779
currency§USD
dateShortInterest§1702598400
forwardEps§0.9
pegRatio§2.04
exchange§NMS
quoteType§EQUITY
shortName§Exelixis, Inc.
longName§Exelixis, Inc.
firstTradeDateEpochUtc§955978200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3d2b06c7-e4e4-3c4b-a972-6c6bfa8d57a3
gmtOffSetMilliseconds§-18000000
targetHighPrice§32.0
targetLowPrice§18.0
targetMeanPrice§26.58
targetMedianPrice§27.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§19
quickRatio§3.619
earningsGrowth§-0.986
grossMargins§0.96239996
ebitdaMargins§0.03728
trailingPegRatio§2.1633
